CRISPR-Cas antimicrobials: Challenges and future prospects

PLoS Pathogens

Volumn 14, Issue 6, 2018, Pages

  Pursey, Elizabeth ^a,b   Sünderhauf, David ^a,b   Gaze, William H ^b   Westra, Edze R ^a   van Houte, Stineke ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM; CRISPR CAS SYSTEM; GENE EDITING; MICROBIAL COMMUNITY; NONHUMAN; BACTERIUM TRANSFORMATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETICS; MICROBIAL VIABILITY;

ANTI-INFECTIVE AGENTS; BACTERIA; CRISPR-CAS SYSTEMS; GENE EDITING; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC ENGINEERING; MICROBIAL VIABILITY; TRANSFORMATION, BACTERIAL;

EID: 85049374102     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006990     Document Type: Article

References (35)

1. Årdal C, Baraldi E, Ciabuschi F, Outterson K, Rex JH, Piddock LJV, et al. To the G20: incentivising antibacterial research and development. Lancet Infect Dis. 2017;17(8):799–801. Epub 2017/07/07. doi: 10.1016/S1473-3099(17)30404-8 pmid: 28689703.
2. Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M, Achieving global targets for antimicrobial resistance. Science. 2016;353(6302):874–5. Epub 2016/08/18. doi: 10.1126/science.aaf9286 pmid: 27540009.
3. Singh V, Braddick D, Dhar PK, Exploring the potential of genome editing CRISPR-Cas9 technology. Gene. 2017;599:1–18. Epub 2016/11/09. doi: 10.1016/j.gene.2016.11.008 pmid: 27836667.
4. Bikard D, Hatoum-Aslan A, Mucida D, Marraffini LA, CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. Cell Host Microbe. 2012;12(2):177–86. doi: 10.1016/j.chom.2012.06.003 pmid: 22901538.
5. Gomaa AA, Klumpe HE, Luo ML, Selle K, Barrangou R, Beisel CL, Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. MBio. 2014;5(1):e00928–13. Epub 2014/01/28. doi: 10.1128/mBio.00928-13 pmid: 24473129
6. Citorik RJ, Mimee M, Lu TK, Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol. 2014;32(11):1141–5. Epub 2014/09/21. doi: 10.1038/nbt.3011 pmid: 25240928.
7. Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014;32(11):1146–50. Epub 2014/10/05. doi: 10.1038/nbt.3043 pmid: 25282355.
8. Yosef I, Manor M, Kiro R, Qimron U, Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci U S A. 2015;112(23):7267–72. Epub 2015/05/18. doi: 10.1073/pnas.1500107112 pmid: 26060300.
9. Kim JS, Cho DH, Park M, Chung WJ, Shin D, Ko KS, et al. CRISPR/Cas9-Mediated Re-Sensitization of Antibiotic-Resistant Escherichia coli Harboring Extended-Spectrum β-Lactamases. J Microbiol Biotechnol. 2016;26(2):394–401. doi: 10.4014/jmb.1508.08080 pmid: 26502735.
10. Sommer MOA, Dantas G, Church GM, Functional characterization of the antibiotic resistance reservoir in the human microflora. Science. 2009;325(5944):1128–31. doi: 10.1126/science.1176950 pmid: 19713526.
11. Thomas CM, Nielsen KM, Mechanisms of, and barriers to, horizontal gene transfer between bacteria. Nat Rev Microbiol. 2005;3(9):711–21. doi: 10.1038/nrmicro1234 pmid: 16138099.
12. Spencer SJ, Tamminen MV, Preheim SP, Guo MT, Briggs AW, Brito IL, et al. Massively parallel sequencing of single cells by epicPCR links functional genes with phylogenetic markers. ISME J. 2016;10(2):427–36. Epub 2015/09/22. doi: 10.1038/ismej.2015.124 pmid: 26394010.
13. Marbouty M, Baudry L, Cournac A, Koszul R, Scaffolding bacterial genomes and probing host-virus interactions in gut microbiome by proximity ligation (chromosome capture) assay. Sci Adv. 2017;3(2):e1602105. Epub 2017/02/17. doi: 10.1126/sciadv.1602105 pmid: 28232956.
14. Theriot CM, Koenigsknecht MJ, Carlson PE, Hatton GE, Nelson AM, Li B, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5:3114. doi: 10.1038/ncomms4114 pmid: 24445449.
15. Jorth P, Turner KH, Gumus P, Nizam N, Buduneli N, Whiteley M, Metatranscriptomics of the human oral microbiome during health and disease. MBio. 2014;5(2):e01012–14. Epub 2014/04/01. doi: 10.1128/mBio.01012-14 pmid: 24692635.
16. Pires DP, Cleto S, Sillankorva S, Azeredo J, Lu TK, Genetically Engineered Phages: a Review of Advances over the Last Decade. Microbiol Mol Biol Rev. 2016;80(3):523–43. Epub 2016/06/01. doi: 10.1128/MMBR.00069-15 pmid: 27250768.
17. Beisel CL, Gomaa AA, Barrangou R, A CRISPR design for next-generation antimicrobials. Genome Biol. 2014;15(11):516. Epub 2014/11/08. doi: 10.1186/s13059-014-0516-x pmid: 25417800.
18. Naduthodi MIS, Barbosa MJ, van der Oost J, Progress of CRISPR-Cas Based Genome Editing in Photosynthetic Microbes. Biotechnol J. 2018. Epub 2018/02/03. doi: 10.1002/biot.201700591 pmid: 29396999.
19. Jiang Y, Qian F, Yang J, Liu Y, Dong F, Xu C, et al. CRISPR-Cpf1 assisted genome editing of Corynebacterium glutamicum. Nat Commun. 2017;8:15179. Epub 2017/05/04. doi: 10.1038/ncomms15179 pmid: 28469274.
20. van Houte S, Ekroth AK, Broniewski JM, Chabas H, Ashby B, Bondy-Denomy J, et al. The diversity-generating benefits of a prokaryotic adaptive immune system. Nature. 2016;532(7599):385–8. Epub 2016/04/13. doi: 10.1038/nature17436 pmid: 27074511.
21. Jiang W, Maniv I, Arain F, Wang Y, Levin BR, Marraffini LA, Dealing with the evolutionary downside of CRISPR immunity: bacteria and beneficial plasmids. PLoS Genet. 2013;9(9):e1003844. Epub 2013/09/26. doi: 10.1371/journal.pgen.1003844 pmid: 24086164.
22. Vercoe RB, Chang JT, Dy RL, Taylor C, Gristwood T, Clulow JS, et al. Cytotoxic chromosomal targeting by CRISPR/Cas systems can reshape bacterial genomes and expel or remodel pathogenicity islands. PLoS Genet. 2013;9(4):e1003454. Epub 2013/04/18. doi: 10.1371/journal.pgen.1003454 pmid: 23637624.
23. Pawluk A, Davidson AR, Maxwell KL, Anti-CRISPR: discovery, mechanism and function. Nat Rev Microbiol. 2018;16(1):12–7. Epub 2017/10/24. doi: 10.1038/nrmicro.2017.120 pmid: 29062071.
24. Borges AL, Davidson AR, Bondy-Denomy J, The Discovery, Mechanisms, and Evolutionary Impact of Anti-CRISPRs. Annu Rev Virol. 2017;4(1):37–59. Epub 2017/07/27. doi: 10.1146/annurev-virology-101416-041616 pmid: 28749735.
25. Pawluk A, Staals RH, Taylor C, Watson BN, Saha S, Fineran PC, et al. Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species. Nat Microbiol. 2016;1(8):16085. Epub 2016/06/13. doi: 10.1038/nmicrobiol.2016.85 pmid: 27573108.
26. Pawluk A, Amrani N, Zhang Y, Garcia B, Hidalgo-Reyes Y, Lee J, et al. Naturally Occurring Off-Switches for CRISPR-Cas9. Cell. 2016;167(7):1829–38. e9. Epub 2016/12/08. doi: 10.1016/j.cell.2016.11.017 pmid: 27984730.
27. Harrington LB, Doxzen KW, Ma E, Liu JJ, Knott GJ, Edraki A, et al. A Broad-Spectrum Inhibitor of CRISPR-Cas9. Cell. 2017. Epub 2017/08/23. doi: 10.1016/j.cell.2017.07.037 pmid: 28844692.
28. Carter SR, Friedman RM. Policy and Regulatory Issues for Gene Drives in Insects: Workshop Report. J. Craig Venter Institute, San Diego, CA, 2016, pp. 1–21.
29. Adelman Z, Akbari O, Bauer J, Bier E, Bloss C, Carter SR, et al. Rules of the road for insect gene drive research and testing. Nat Biotechnol. 2017;35(8):716–8. doi: 10.1038/nbt.3926 pmid: 28787415.
30. De Gelder L, Williams JJ, Ponciano JM, Sota M, Top EM, Adaptive plasmid evolution results in host-range expansion of a broad-host-range plasmid. Genetics. 2008;178(4):2179–90. doi: 10.1534/genetics.107.084475 pmid: 18430943.
31. Heuer H, Fox RE, Top EM, Frequent conjugative transfer accelerates adaptation of a broad-host-range plasmid to an unfavorable Pseudomonas putida host. FEMS Microbiol Ecol. 2007;59(3):738–48. Epub 2006/10/24. doi: 10.1111/j.1574-6941.2006.00223.x pmid: 17059480.
32. Harrison E, Guymer D, Spiers AJ, Paterson S, Brockhurst MA, Parallel compensatory evolution stabilizes plasmids across the parasitism-mutualism continuum. Curr Biol. 2015;25(15):2034–9. Epub 2015/07/16. doi: 10.1016/j.cub.2015.06.024 pmid: 26190075.
33. Bikard D, Barrangou R, Using CRISPR-Cas systems as antimicrobials. Curr Opin Microbiol. 2017;37:155–60. Epub 2017/09/05. doi: 10.1016/j.mib.2017.08.005 pmid: 28888103.
34. Unckless RL, Clark AG, Messer PW, Evolution of Resistance Against CRISPR/Cas9 Gene Drive. Genetics. 2017;205(2):827–41. Epub 2016/12/10. doi: 10.1534/genetics.116.197285 pmid: 27941126.
35. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, et al. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. 2015;13(11):722–36. Epub 2015/09/28. doi: 10.1038/nrmicro3569 pmid: 26411297.